News | August 19, 2025
Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The agreement complements other PPAs for Sandoz production sites globally
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
Cenexi reports an EBITDA breakeven for the quarter
Subscribe To Our Newsletter & Stay Updated
